NOX4 and diabetes mellitus: Taken together, these data clearly support a significant role for NOX4 in regulating CB-ECFC dysfunction in diabetes, whilst highlighting selective targeting of downstream angiogenic signalling as a potential innovative approach to augment therapeutic efficacy of both endogenous circulating ECFCs and allogeneic CB-ECFCs in this setting.